Securian Asset Management Inc. Sells 107 Shares of Repligen Co. (NASDAQ:RGEN)

Securian Asset Management Inc. decreased its position in shares of Repligen Co. (NASDAQ:RGEN) by 2.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,937 shares of the biotechnology company’s stock after selling 107 shares during the quarter. Securian Asset Management Inc.’s holdings in Repligen were worth $567,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in RGEN. Atria Investments Inc grew its stake in shares of Repligen by 67.9% during the 3rd quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 1,295 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of Repligen during the 3rd quarter worth $306,000. CIBC Asset Management Inc bought a new position in shares of Repligen during the 3rd quarter worth $242,000. Natixis Advisors LLC grew its stake in shares of Repligen by 53.6% during the 3rd quarter. Natixis Advisors LLC now owns 33,625 shares of the biotechnology company’s stock worth $5,004,000 after acquiring an additional 11,731 shares during the period. Finally, Thrivent Financial for Lutherans grew its stake in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after acquiring an additional 36,773 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Stock Up 5.7 %

Shares of NASDAQ RGEN opened at $150.62 on Monday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.23. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.44 billion, a price-to-earnings ratio of -295.33, a PEG ratio of 4.54 and a beta of 0.95. The business has a 50-day moving average of $157.19 and a 200-day moving average of $148.52.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.